Physician profile
Shu Chin
NPI 1881663904
$10,133.66
in general payments reported to CMS, 2019-2025
31 companies · $938 in 2025
The $938 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,028 · 2020: $1,126 · 2021: $2,104 · 2022: $1,901 · 2023: $1,201 · 2024: $835 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,975.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,938.30 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,578.43 | 2019-2025 | Jardiance |
| Gilead Sciences, INC. | $908.28 | 2019-2025 | |
| Amgen INC. | $816.47 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $734.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $669.90 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $526.38 | 2019-2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $353.15 | 2019-2022 | |
| Lilly USA, LLC | $334.13 | 2019-2024 | Jardiance, Trulicity, Mounjaro |
| Biogen, INC. | $271.42 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $261.00 | 2022-2025 | |
| Pfizer INC. | $246.79 | 2020-2025 | |
| Novo Nordisk INC | $242.24 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $237.73 | 2021-2024 | Linzess, Viberzi |
| Esperion Therapeutics, INC. | $211.22 | 2021-2024 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $131.99 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $117.79 | 2019 | |
| Ironwood Pharmaceuticals, INC | $99.21 | 2019-2023 | Linzess |
| Kowa Pharmaceuticals America, INC. | $63.63 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.46 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $62.24 | 2022-2023 | Quviviq |
| Horizon Therapeutics Plc | $49.14 | 2021-2023 | Krystexxa |
| Aimmune Therapeutics, INC. | $45.46 | 2024-2025 | Zenpep |
| Ibsa Pharma INC. | $41.01 | 2021 | |
| Nestle Healthcare Nutrition INC. | $27.03 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.91 | 2020 | |
| Eisai INC. | $19.04 | 2023 | |
| Allergan, INC. | $17.48 | 2019 | |
| Axsome Therapeutics, INC. | $17.08 | 2025 | Auvelity |
| Seqirus USA INC | $13.58 | 2025 | Flucelvax |
| Azurity Pharmaceuticals, INC. | $12.70 | 2023 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shu Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.